US Patent

US9339507 — Treprostinil administration by inhalation

Formulation · Assigned to United Therapeutics Corp · Expires 2028-03-10 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of administering treprostinil using a metered dose inhaler.

USPTO Abstract

Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Drugs covered by this patent

Remodulin (TREPROSTINIL) · United Therap

Patent Metadata

Patent number: US9339507
Jurisdiction: US
Classification: Formulation
Expires: 2028-03-10
Drug substance claim: No
Drug product claim: Yes
Assignee: United Therapeutics Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.